Clinical trials confirm verapamil’s beneficial effects on β-cells via downregulation of TXNIP and IGFBP3 and upregulation of IGF-1 signaling in type 1 diabetes (T1D) patients [45]. This evidence concerns the gene IGF1 and type 1 diabetes mellitus.